Annual magnetic resonance cholangiopancreatography surveillance outcomes in individuals with primary sclerosing cholangitis
Internal Medicine Journal · 2026-06 · 56 (6) · 1026-1032
DOI: 10.1111/imj.70435 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 11.04.2026. Verfasst von Gary Dezhi Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sir Charles Gairdner Hospital, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Cholangiopancreatography, Magnetic Resonance, Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Annual surveillance for cholangiocarcinoma using magnetic resonance cholangiopancreatography (MRCP) has been recommended in primary sclerosing cholangitis (PSC) to improve the associated dismal outcomes. However, data are limited.
Aims
To compare the outcomes of surveillance versus non‐surveillance in patients with PSC.
Methods
A retrospective cohort of patients with PSC at a liver transplant hospital with hepatologist‐directed MRCP surveillance were identified. The surveillance group underwent a MRCP every 12 ± 3 months for at least 70% of the follow‐up period. Patients were followed from their first MRCP to cholangiocarcinoma diagnosis, liver transplantation, death or the 30 April 2023.
Results
The surveillance group with 108 patients (68%) and non‐surveillance group with 50 patients (32%) were similar at baseline, with the median age at PSC diagnosis 38 years (range: 7–78 years), 91 males (59%) and the median duration of MRCP surveillance 86 months (range: 10–257 months). Cholangiocarcinoma was diagnosed in 14 patients (9%) (intrahepatic, n = 10; extrahepatic, n = 4). Surveillance MRCP detected one cholangiocarcinoma of the six patients diagnosed in the surveillance cohort, while 10 patients were diagnosed with cholangiocarcinoma following symptoms or raised liver enzymes. Overall, cumulative survival at 3 and 5 years was significantly improved in the surveillance group compared with the non‐surveillance group in multivariate models, adjusting for age, cirrhosis and presence of cholangiocarcinoma (97% vs 77%, and 94% vs 69%, respectively; P < 0.001).
Conclusion
MRCP surveillance did not detect early cholangiocarcinoma or improve cholangiocarcinoma survival in this retrospective cohort of PSC patients; however, surveillance was associated with improved overall survival compared to no surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
- Medical School, The University of Western Australia, Perth, Western Australia, Australia.
ORCID-Profile: Gary Dezhi Zhang
Zitieren
APA
Zhang, G. D., Attree, C., Irani, N., Tibballs, J., Ferguson, J., Bertot, L. C., Wallace, M., Smith, B., Garas, G., Jeffrey, G., Adams, L. A., & MacQuillan, G. (2026). Annual magnetic resonance cholangiopancreatography surveillance outcomes in individuals with primary sclerosing cholangitis. Internal Medicine Journal, 56(6), 1026-1032. https://doi.org/10.1111/imj.70435
Vancouver
Zhang GD, Attree C, Irani N, Tibballs J, Ferguson J, Bertot LC, et al. Annual magnetic resonance cholangiopancreatography surveillance outcomes in individuals with primary sclerosing cholangitis. Internal Medicine Journal. 2026;56(6):1026-1032. doi:10.1111/imj.70435
BibTeX
@article{Zhang2026,
author = {Zhang, Gary Dezhi and Attree, Chloe and Irani, Nazneen and Tibballs, Jonathan and Ferguson, John and Bertot, Luis Calzadilla and Wallace, Michael and Smith, Briohny and Garas, George and Jeffrey, Gary and Adams, Leon Anton and MacQuillan, Gerry},
title = {Annual magnetic resonance cholangiopancreatography surveillance outcomes in individuals with primary sclerosing cholangitis},
journal = {Internal Medicine Journal},
year = {2026},
volume = {56},
number = {6},
pages = {1026--1032},
doi = {10.1111/imj.70435}
}
EUVIMED